Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy

Trial Status: temporarily closed to accrual

This phase II trial studies how well selinexor in combination with carfilzomib, daratumumab or pomalidomide, and dexamethasone works for the treatment of patients with multiple myeloma that is relapsing on current therapy. Selinexor is in a class of medications called selective inhibitors of nuclear export. It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Carfilzomib is a type of drug called a proteasome inhibitor that works by marking damaged proteins that are needed to be destroyed by the cell for survival which may kill cancer cells. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving selinexor with carfilzomib, daratumumab or pomalidomide, and dexamethasone may kill more cancer cells in patients with multiple myeloma that is relapsing on current therapy.